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Why was the collaboration set up?
DynaHEALTH is a research consortium funded by the
European Commission through the Horizon 2020 research
programme. It was established to help solve the societal
challenge of an ageing population and the associated bur-
den of non-communicable diseases related to obesity and
type 2 diabetes (T2D). The consortium brings together
European researchers and datasets to build an empirical
model of unhealthy ageing, with a longitudinal perspective,
in which causal, bi-directional, mediating and confounding
factors operate at a multi-dimensional level (Figure 1).
The unhealthy ageing pathways often link altered adi-
posity in early life, early-onset obesity, T2D and the further
accumulation of other chronic physical and mental non-
communicable diseases in older ages. At each stage of the
life-course there is potential to intervene either on sus-
pected biological causes via classical clinical approaches,
or other plausible causative pathways1 via integrated pub-
lic health interventions (Figure 1). Successful interventions
in early life have the potential to reduce subsequent invest-
ments in later life. Scientific collaborations in epidemiology
and public health such as DynaHEALTH are built on a
long-standing tradition of collecting prospective data.
Moving on to the era of open sciences policy,2 meta-data
analysis, the FAIR data principle (Findable, Accessible,
Interoperable and Reusable) and the General Data
Protection Regulation (GDPR), we must direct this public
legacy in such a way as to better inform both policy makers
and practitioners on complex patient and public health issues.
Essentially, we must operate data to move beyond
association studies and explore how the psychosocial fac-
tors, usually classified as confounders in medicine
(Figure 2), can be analysed to help their operationalization
and integration into healthcare programmes. Despite no
apparent consensus in the literature on a single definition
of psychosocial health, DynaHEALTH is referring to the
following WHO definition3 as a guiding principle: ‘a state
of wellbeing in which every individual realises their own
potential, can cope with the normal stresses of everyday
life, can work productively and fruitfully, and is able to
make a contribution to their community’.4,5
Conceptual framework of DynaHEALTH: The rela-
tionships between psychosocial factors, glycaemic health4,5
and healthy ageing, including a reduced risk of T2D and
cardiovascular diseases, may be conceptualized in several
different ways. It is an integral part of the DynaHEALTH
consortium to develop these concepts and translate them
into corresponding analytical study designs compatible
with available data (Figure 2).
At the core of DynaHEALTH is the well-established ob-
servational and likely causal relationship between stages of
disease development: firstly between adiposity and the risk
of deteriorating glycaemic health and eventual T2D,6–8 and
secondly between T2D and the risk of non-communicable
diseases including stroke, coronary heart diseases, dementia
and Alzheimer’s disease. All of these (pre-)clinical stages of
disease development may share genetic, biological, lifestyle
and psychosocial causes, but for both stages considerable
knowledge gaps remain concerning action and impact on
policies. We lack knowledge on identification of specific
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causal factors, the pathway(s) they operate through and
their life-course aspects (Figure 2).
While considering these relationships, a number of hy-
potheses may be posed about the role of psychosocial fac-
tors throughout the life-course from the foetal period to
old age.
• Unidirectional causality hypothesis: Adverse psychoso-
cial factors play a causal role in the development and
worsening of adiposity, or of particular types of adipos-
ity, with different relationships to glycaemic health and
risk of T2D and subsequent morbidities.
• Pleiotropy and interaction hypothesis: In the case of cau-
sality in such life-course pathways, it can be hypothesized
that causal reactions to one or a set of psychosocial fac-
tors reflect underlying commonality influencing the clini-
cal outcome in the life-course process. This can be
analysed by exploring how the psychosocial factors may
modify or contribute to the core relations between adipos-
ity, glycaemic health, risk of T2D and the later onset of
cardiovascular diseases, so that each of these relationships
becomes stronger when the individuals are exposed to ad-
verse psychosocial factors.
Figure 1. Illustration of the conceptual framework for unhealthy ageing from early life to old age. From a life-course perspective, it suggests that clini-
cal events accumulate or lead to each other, and co-occur with factors that either can or cannot be modified. (T2D¼type 2 diabetes, NCD¼non-com-
municable disease). (Reproduced from https://www.dynahealth.eu/ with permission).
Figure 2. Physiological, lifestyle and psychosocial factors and stressors acting on life-course pathways linking altered adiposity in early life to non-
communicable diseases at older ages.
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• Bi-directional causality hypothesis: The relationships
between adiposity, glycaemic health, T2D risk and
cardiovascular diseases are worsening one single or set of
psychosocial factor(s) in such a way that vicious cycles
of deterioration are promoted.
• Critical period hypothesis: There are specific time peri-
ods within the life-course during which psychosocial fac-
tors have a greater impact on these unhealthy ageing
pathways.
• Biological conversion hypothesis: The effects of psycho-
social factors can be ‘transformed’ into causal biological
effects. In this case, we want to identify the persisting
structural effects during early life and the functional
mechanisms, e.g. by epigenetic regulation of gene expres-
sion or changes in the metabolite profiles.
• Gene–environment hypothesis: The genetic variation be-
tween individuals may modify the transformation of psy-
chosocial factors into biological effects.
The impact on future public health recommendations
and new technologies strongly depends on the capacity to
test this set of hypotheses. This requires large statistical
power or the development of a specific study design that is
enabled by building sustainable and targeted datasets
through consortia such as DynaHEALTH.
Who is in the consortium?
To date, there is no single longitudinal study with a suffi-
cient density of data and long-term follow-up to allow a
life-course study of unhealthy ageing via changes in adult
glycaemic health. Nonetheless, there is a wealth of some-
what scattered, prospective studies with complementary
designs which can be leveraged to study the dynamic deter-
minants of life-long glycaemic health.
The DynaHEALTH consortium is a repertoire of hu-
man studies with longitudinal design where key variables
have been inventoried for meta-analysis or triangulation of
evidence to test specific epidemiological concepts. The
data we are analysing are from two main types of study
design: prospective longitudinal surveys and randomized
controlled trials (RCT). The consortium currently consists
of 20 studies (Table 1) with data from eight European
Countries (Figure 3) on up to 1 368 699 participants
(Figures 4). The oldest living participants are from the
Helsinki Birth Cohort Study (HBCS) born in 1934 in the
Finnish city of Helsinki, whereas the youngest were
born in April 2018 in the NIGOHEALTH RCT in
Granada, Spain. These 20 studies consist of 12 general
population cohorts9–20 of which six have a focus on later
life and ageing with data beyond 65 years of age.9–11,17–19
Table 1. List of cohorts and randomized controlled trials participating in the DynaHEALTH consortium and their contacts
Abbreviation Cohort full name Contact
HBCS Helsinki Birth Cohort Study johan.eriksson@helsinki.fi
CSHRR Copenhagen School Health Record Register Jennifer.Lyn.Baker@regionh.dk
DFBC Dutch Famine Birth Cohort t.j.roseboom@amc.uva.nl
DCD Danish conscription database elme@sund.ku.dk
CPC Copenhagen Perinatal Cohort elme@sund.ku.dk
CIHVR Copenhagen Infant Health Visitor Records Jennifer.Lyn.Baker@regionh.dk
NFBC1966 Northern Finland Birth Cohort 1966 NFBCprojectcenter@oulu.fi
NFBC1986 Northern Finland Birth Cohort 1986 NFBCprojectcenter@oulu.fi
RS Rotterdam Study m.a.ikram@erasmusmc.nl
OULU1935 Oulu cohort study NFBCprojectcenter@oulu.fi
OULU1945 Oulu cohort study NFBCprojectcenter@oulu.fi
POGO German GDM Postpartum Outcomes in Women with
Gestational Diabetes and their Offspring
sandra.hummel@lrz.uni-muenchen.de
GENERATION R Generation R Study v.jaddoe@erasmusmc.nl or
j.felix@erasmusmc.nl
PREOBE Excellence Project PREOBE ccampoy@ugr.es
Abbreviation Randomized controlled trials full name Contact
CHOP Childhood Obesity Program Berthold.Koletzko@med.uni-muenchen.de
RADIEL Finnish Gestational Diabetes Prevention Study johan.eriksson@helsinki.fi
COGNIS A Neurocognitive and Immunological Study of a
New Formula for Healthy Infants
Maria.Rodriguez@ordesa.es
WOMB WOMB kids t.j.roseboom@amc.uva.nl
NIGOHEALTH Nutritional Intervention during Gestation and Offspring health Ricardo.Rueda@abbott.com
This table has been adapted from https://www.dynahealth.eu/ with permission.
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Three high-risk cohorts21–23 follow populations of off-
spring born to mothers with a risk of gestational diabetes
(GDM), either via high pre-pregnancy body mass index
(BMI), previous history of GDM or other known risk fac-
tors. Five RCTs focus24–28 on pre-conception, prenatal and
early-life interventions to improve maternal health and
child development.
How often have they been followed up?
Altogether there are 17 time periods in which data has
been prospectively collected from the pre-conception pe-
riod until age 80 years of age (see Figure 4 for study time-
lines). In addition, most follow-up time periods have data
from at least two cohorts to allow replication or the use of
imputation across studies. The cohort-specific descriptions
of follow-ups are provided in Supplementary File 1, avail-
able as Supplementary data at IJE online.
What has been measured?
The DynaHEALTH Consortium offers the potential to ex-
tend our knowledge about the childhood origin of adult
metabolic diseases and focus on key exposures during preg-
nancy and early life and glycaemic, cardiovascular and
metabolic outcomes in later life.
The consortium data harmonization policy is following
a research-based focus where only variables defined in
template-based analytical plans are being proposed for har-
monization. The set of common harmonized data for
Figure 3. Map of studies participating in DynaHEALTH (sample size in brackets) by country. The size of the circle indicates the relative size of the
study. Red arrows and stars show the participating centres of the multinational CHOP study.
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DynaHEALTH has followed these steps adapted from
Rolland et al.29
• Identification of the research questions that the harmo-
nized data set is required to answer.
• Identification of the high-level data concepts required to
answer those questions as described in the conceptual
framework of DynaHEALTH.
• Assessment of data availability for data concepts.
• Inventory of sets of pre-harmonized data due to collabo-
ration in previous consortiums.
• Development of analytical plans.
• Development of harmonized data following the FAIR
data management principles.
Retrospective harmonization of data, especially the psy-
chosocial factors, can be a costly and sometimes an impos-
sible process. In all cases analytical procedures shall
account for the source of heterogeneity in inference which
is addressed by the consortium via suitable meta-analytical
processes and external replication.
In many cases, the cohort studies have been able to link
with national, country-specific registers. These include
databases such as population, hospital, education and em-
ployment registers, health visitor records, hospital and
school records. This gives us the opportunity to use objec-
tive data alongside self-reported responses. It also enables
us to obtain more information than collected from the sur-
veys, such as clinical diagnosis, hospital visits, medication
use and cause of death. We also use information from these
registers to conduct attrition analyses in the case of partici-
pants lost during follow-up. In summary, Tables 2 and 3
provide an overview of data available within each cohort.
The co-ordinating team in DynaHEALTH has created, and
regularly updates, a detailed inventory showing available
data within each cohort, time points and method of collec-
tion. This allows researchers to easily identify other data
sources they could use to strengthen their study results, test
a hypothesis or methodology, take a life-course approach
by using data at earlier or later time points or investigate
historical or cultural trends. A detailed inventory of what
has been measured in each cohort can also be accessed on
the DynaHEALTH website (http://dynahealth.eu/).
Pregnancy
A wealth of data is available from early life, as 16 of the
study populations were established during pregnancy or
even during the pre-conception period, following a cohort
Figure 4. DynaHEALTH datasets by size (in brackets), type, length and timing across the life-course, from the oldest study (top) to the youngest (bot-
tom), separately for epidemiological longitudinal data and randomized controlled trials. White circles represent follow-up points, stars represent im-
plementation of intervention and ‘R’ represents register-based datasets. Abbreviations are given in Table 1. (Reproduced from https://www.
dynahealth.eu/ with permission).
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design or randomized clinical intervention (Figure 4).
Maternal anthropometric measures such as height and
weight have been recorded at various time points through-
out pregnancy and in some studies at delivery, allowing the
calculation of gestational weight gain. Blood samples have
been taken from the mother during pregnancy and from
the umbilical cord at birth enabling measures such as glu-
cose, insulin or cardiovascular markers to be obtained.
Additionally, extraction of DNA has enabled genotyping
and DNA methylation arrays. Nuclear magnetic resonance
(NMR)- or mass spectrometry-based metabolomics are
now also available in a number of cohorts. Questionnaires
were administered in some cohorts during pregnancy to
collect social and demographic data such as work-related
and household information. Health behaviours included
smoking and alcohol use during pregnancy.
Childhood
Anthropometric information such as weight and height is
particularly dense throughout early childhood as this was
collected as part of routine practice within the health and
welfare clinics in many European countries. Calculation of
the BMI has allowed modelling of growth curves and ena-
bles subsequent extraction of growth traits such as age at
adiposity peak and rebound, and peak weight and height
velocity. In addition, the health visitor records are particu-
larly beneficial in obtaining early-life exposures such as
age of achievement of common motor and cognitive
developmental milestones and breastfeeding duration.
Some cohorts have also collected biological samples during
this time period and more recently established studies in-
clude detailed body composition measurements such as
body fat percentage and skinfold thickness. Many studies
include questionnaire responses in relation to a host of life-
style information such as dietary intake, physical condition
and activity, sleep duration and quality, parental smoking
and alcohol use, parental occupations and maternity leave.
Adolescence
Height, weight and BMI are readily available for partici-
pants during adolescence across the majority of cohorts, al-
though measurements are less regular than in childhood.
Some cohorts have collected biological samples that have
allowed the inclusion of epigenetic and metabolomics data
in collaborative analyses. Social information has been col-
lected by questionnaire, primarily related to the social sta-
tus of the parents. However, questions have been asked of
the participants about their own smoking, alcohol and
drug use, how they spend their leisure time and their typi-
cal diet. In addition, some cohorts are linked to registered
data on school performance.
Adulthood and old age
Anthropometric measures are readily available at many
stages of adulthood, as well as blood samples. These have
Table 3. Data available or being collected for clinical trials in DynaHEALTH (¼ data available, x¼ data not available, - ¼no data
collection at this time point)
Indicator of interest CHOP RADIEL COGNIS WOMB NIGOHEALTH
Pregnancy
Anthropometric measures     
Blood samples   
Gestational diabetes     
Socio-economic indicators     
Health behaviours     
Childhood (birth to 12 y)
Anthropometric measures     
Growth modelling     
Blood samples     
Developmental milestones     
Early nutrition     
Family lifestyle information     
Adolescence (13–18 y)
Anthropometric measurements - -  - -
Blood samples - -  - -
Socio-economic indicators - -  - -
Health behaviours - -  - -
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been used to derive a host of indicators including common
cardio-metabolic biomarkers such as glucose, insulin and
lipid levels and have been used to derive epigenetic and
metabolomics information. Almost all cohorts have a vast
array of psychosocial variables from questionnaires and
national registers. Extensive information is available on
employment and work-related information such as type of
occupation, hours of work, employment history and in-
come. Educational level and occupational training of the
participant and their parents is also reported in many
cohorts. We can obtain a wealth of information relating to
family life, such as marital status, number of children,
housing situation and living environment and their changes
over time. Many cohorts have collected a range of back-
ground information relating to lifestyle and health behav-
iours including diet, physical activity, smoking and alcohol
consumption. For old-age populations especially, measures
of metabolic traits and cognition have been collected.
What has DynaHEALTH found? Key findings
and publications
A full list of publications arising from the DynaHEALTH ac-
tion can be found on the project website (https://www.dyna
health.eu/publications-map). DynaHEALTH aims to
operationalize a data-driven approach to provide evidence
for the bio-psychosocial pathways of unhealthy ageing asso-
ciated with alteration of glycaemic health. This should also
be examined in the context of strong health inequalities and
complex transgenerational issues operating from the pre-
conceptional period onwards. In support of others, we have
identified several metabolic alterations in mothers with obe-
sity and GDM in comparison with normal weight mothers,
associated with offspring health, including changes in DNA
methylation,30 gene expression31 and/or later metabolic out-
comes.32,33 From an age-related perspective, DynaHEALTH
research has also contributed evidence to support links be-
tween glucose metabolism, psychosocial factors and the age-
ing process.34,35
As described in the above sections it is now essential to
use and model the data to explore the nature of observed
associations as a pre-requisite of informed decisions for
prevention, intervention and policy making.36 For exam-
ple, we have found little evidence for causality between
maternal BMI during pregnancy and the child’s risk of obe-
sity. Rather, it is explained by genetic transmission of BMI
variants interacting with a stressful, obesogenic environ-
ment.37 This is supported by a further study showing that
risk scores based on genetic variants linked to specific bio-
logical pathways influence body fat development from
early life onwards. This study found an association be-
tween a genetic risk score based on adult BMI, and BMI at
adiposity peak during infancy and abdominal fat measures
at the age of 6 years.38
Ongoing research by the consortium is supporting the
joint effects of bio-psychosocial factors on glucose metabo-
lism.4 We have also established an opportunity to change
the trajectory of an individual from childhood adiposity to
T2D in later life.39
Strengths and weaknesses: how does
DynaHEALTH offer a unique opportunity
and what are the main challenges faced
by the consortium?
DynaHEALTH exemplifies the wealth of prospective data
collected in Europe that can be harnessed to enhance our
understanding of healthy ageing by modelling the relation-
ship between glycaemic health and psychosocial factors
throughout the life-course. When combined, these data of-
fer immense potential to inform future health policy in
Europe. The data are organized to enable direct replication
under collaborative agreements within the consortium and
a number of observations can also be meta-analysed. While
sample size allowing statistical power is deemed essential
for robust evidence-based strategies, it is also important to
combine study designs to validate findings under different
statistical assumptions. DynaHEALTH’s additional
strength is to include data from RCTs. Finally, the
DynaHEALTH consortium includes both longitudinal birth
cohorts and ageing cohorts from the same geographical lo-
cation. This is the case in Northern Finland (NFBC1966/86
and Oulu 1935/45), the Rotterdam area (Rotterdam Study
and Generation R Study) and in Copenhagen (CSHRR).
The critical mass of data, expertise and long-term col-
laboration brought together in DynaHEALTH offers a sig-
nificant resource. However, the main challenge faced by
the consortium is how best to combine the characteristics
of the cohorts involved. The cohorts were established for
their own individual purposes before being brought to-
gether under this project and the methods of data collec-
tion have thus not been standardized a priori across the
consortium. Therefore, some consideration is required for
the transferability of the statistical models and there are
similar challenges in harmonizing the data. In addition,
this is an international project and therefore there are dif-
ferences between studies and countries in technology, ques-
tionnaire data and bio-specimen collection methods,
terminology and diagnosis definitions, country-specific
measurement techniques and ethical requirements.
However, the consortium has made significant progress in
overcoming these challenges and the overarching opportunity
for DynaHEALTH is that all studies provide rich data on
similar key exposures and the outcome measures of interest.
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Currently, there is no single cohort with data available
from pre-conception to old age including information re-
lating to both biological and psychosocial measures in rela-
tion to health outcomes. This consortium provides unique
access to a number of studies ranging over different time
periods encompassing different life stages, that will enable
us to use a life-course approach to model the risk of poor
glycaemic health and T2D, and to better understand the
dynamics of how this will change in response to other fac-
tors throughout the life stages.
The collaborating cohorts include participants from eight
European countries representing general, high-risk, obese
and diabetic populations. This broad range of populations
enables evaluation of the consistency of results and thus pro-
vides greater generalizability of consortium findings. We also
have access to expert collaborators from academia and indus-
try with expertise in life-course epidemiology, developmental
biology, genetics and epigenetics, metabolomics, biostatistics,
clinical nutrition, health care, brain imaging, econometrics
and European policy and knowledge management.
The key value of DynaHEALTH is that we foresee the
well-established, strong collaboration being used as a plat-
form for many further efforts and continuing beyond the
Horizon 2020 programme. Thus, this consortium may pro-
vide valuable assistance to investigators planning new cohort
studies in terms of study design and the addition of new
ideas, providing advice about data collection and manage-
ment. DynaHEALTH will also offer an example of
assumption-based modelling of the dynamic relations of the
psychosocial and metabolic factors in the pathways of adi-
posity -> glycaemic health –> T2D risk –> risk of cardiovas-
cular disease –> unhealthy ageing throughout the life course.
Can I get hold of the data? Where can I find
out more?
The project is co-ordinated by the Centre for Life Course
Health Research and the Northern Finland Cohort Project
Centre at the University of Oulu in Finland. Further details
on DynaHEALTH are available from the website: www.
dynahealth.eu. The studies are approved by the local insti-
tutional review boards. Written informed consent has been
obtained for participants. There is no central repository for
the data and each participating cohort has its own policy
for data sharing.
The DynaHEALTH project legacy will be a collabora-
tive action that will invite researchers with longitudinal
life-course data to engage with us via the website (https://
www.dynahealth.eu/contact). To ensure continuity, the
relevant section of the website and a light governance will
remain to bring sustainability to the consortium and sup-
port the testing of its scientific concept.
Supplementary data
Supplementary data are available at IJE online.
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